• Immunohistochemistry analysis of paraffin-embedded human human testis (left) and prostate cancer (right) tissues with DAB staining using AR monoclonal antibody.
  • Western blot analysis using AR monoclonal antibody against K562 (1) , Jurkat (2) and LNCaP (3) cell lysate.

Anti-AR antibody [2H8] (STJ97846)

SKU:
STJ97846

Current Stock:
Host: Mouse
Applications: WB/IHC/IF/ELISA
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-Androgen receptor is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications.
Clonality: Monoclonal
Clone ID: 2H8
Conjugation: Unconjugated
Isotype: IgG1
Formulation: Liquid in PBS containing 0.03% Sodium Azide, 0.5% BSA, 50% Glycerol.
Purification: Affinity purification
Dilution Range: WB 1:500-1:2000
IHC 1:200-1:1000
ELISA 1:10000
IF 1:50-200
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: AR
Gene ID: 367
Uniprot ID: ANDR_HUMAN
Specificity: AR Monoclonal Antibody detects endogenous levels of AR protein.
Immunogen: Purified recombinant fragment of human AR expressed in E. Coli.
Post Translational Modifications Sumoylated on Lys-388 (major) and Lys-521. Ubiquitinated. Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked polyubiquitination by RNF6 modulates AR transcriptional activity and specificity. Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. Phosphorylation by TNK2 enhances the DNA-binding and transcriptional activity and may be responsible for androgen-independent progression of prostate cancer. Phosphorylation at Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. Phosphorylation by PAK6 leads to AR-mediated transcription inhibition. Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.
Function Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation. Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3. Isoform 3: Lacks the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones. Isoform 4: Lacks the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.
Protein Name Androgen Receptor
Dihydrotestosterone Receptor
Nuclear Receptor Subfamily 3 Group C Member 4
Database Links Reactome: R-HSA-3371497
Reactome: R-HSA-383280
Reactome: R-HSA-4090294
Reactome: R-HSA-5625886
Reactome: R-HSA-5689880
Reactome: R-HSA-8940973
Cellular Localisation Nucleus
Cytoplasm
Detected At The Promoter Of Target Genes
Predominantly Cytoplasmic In Unligated Form But Translocates To The Nucleus Upon Ligand-Binding
Can Also Translocate To The Nucleus In Unligated Form In The Presence Of Rack1
Alternative Antibody Names Anti-Androgen Receptor antibody
Anti-Dihydrotestosterone Receptor antibody
Anti-Nuclear Receptor Subfamily 3 Group C Member 4 antibody
Anti-AR antibody
Anti-DHTR antibody
Anti-NR3C4 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance